Related references
Note: Only part of the references are listed.MEK inhibitors under development for treatment of non-small-cell lung cancer
Chul Kim et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2018)
Discovery of a small-molecule inhibitor of specific serine residue BAD phosphorylation
Vijay Pandey et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2018)
MEK inhibitors in oncology: a patent review (2015-Present)
Debarshi Kar Mahapatra et al.
EXPERT OPINION ON THERAPEUTIC PATENTS (2017)
Comprehensive Evaluation of TFF3 Promoter Hypomethylation and Molecular Biomarker Potential for Prostate Cancer Diagnosis and Prognosis
Maibritt Norgaard et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2017)
Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial
David Planchard et al.
LANCET ONCOLOGY (2017)
Convergent Akt activation drives acquired EGFR inhibitor resistance in lung cancer
Kirstine Jacobsen et al.
NATURE COMMUNICATIONS (2017)
Hypomethylation associated enhanced transcription of trefoil factor-3 mediates tamoxifen-stimulated oncogenicity of ER plus endometrial carcinoma cells
Vijay Pandey et al.
ONCOTARGET (2017)
Drug combination approach to overcome resistance to EGFR tyrosine kinase inhibitors in lung cancer
Christy W. S. Tong et al.
CANCER LETTERS (2017)
Overexpression of trefoil factor 3 (TFF3) contributes to the malignant progression in cervical cancer cells
Zhaohu Yuan et al.
CANCER CELL INTERNATIONAL (2017)
Dabrafenib plus trametinib in patients with previously treated BRAFV600E-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial
David Planchard et al.
LANCET ONCOLOGY (2016)
CXCR4 and CXCR7 Mediate TFF3-Induced Cell Migration Independently From the ERK1/2 Signaling Pathway
Julia Dieckow et al.
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE (2016)
Trefoil factor 3 (TFF3) enhances the oncogenic characteristics of prostate carcinoma cells and reduces sensitivity to ionising radiation
Omesha Perera et al.
CANCER LETTERS (2015)
BRAF Alterations as Therapeutic Targets in Non-Small-Cell Lung Cancer
Tu Nguyen-Ngoc et al.
JOURNAL OF THORACIC ONCOLOGY (2015)
Trefoil Factor 3 as a Novel Biomarker to Distinguish Between Adenocarcinoma and Squamous Cell Carcinoma
Xiao-Nan Wang et al.
MEDICINE (2015)
Trefoil factors (TFFs) are increased in bronchioalveolar lavage fluid from patients with chronic obstructive lung disease (COPD)
Niels-Erik Viby et al.
PEPTIDES (2015)
Better Together: Targeted Combination Therapies in Breast Cancer
Elisa Zanardi et al.
SEMINARS IN ONCOLOGY (2015)
TFF3 and HER2 expression and their correlation with survival in gastric cancer
Jianchun Gu et al.
TUMOR BIOLOGY (2015)
Melatonin Sensitizes H1975 Non-Small-Cell Lung Cancer Cells Harboring a T790M-Targeted Epidermal Growth Factor Receptor Mutation to the Tyrosine Kinase Inhibitor Gefitinib
Miyong Yun et al.
CELLULAR PHYSIOLOGY AND BIOCHEMISTRY (2014)
Cancer Stem Cells: Biological Functions and Therapeutically Targeting
Marius Eugen Ciurea et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2014)
MEK inhibition in non-small cell lung cancer
Thomas E. Stinchcombe et al.
LUNG CANCER (2014)
Three-Dimensional Lung Tumor Microenvironment Modulates Therapeutic Compound Responsiveness In Vitro - Implication for Drug Development
Jason E. Ekert et al.
PLOS ONE (2014)
Dimerization of the kinase ARAF promotes MAPK pathway activation and cell migration
Juliane Mooz et al.
SCIENCE SIGNALING (2014)
Trefoil factor 3 promotes metastatic seeding and predicts poor survival outcome of patients with mammary carcinoma
Vijay Pandey et al.
BREAST CANCER RESEARCH (2014)
Increased trefoil factor 3 levels in the serum of patients with three major histological subtypes of lung cancer
Yiqing Qu et al.
ONCOLOGY REPORTS (2012)
Trefoil factors: Tumor progression markers and mitogens via EGFR/MAPK activation in cholangiocarcinoma
Kanuengnuch Kosriwong et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2011)
KRAS Mutant Lung Cancer Cells Are Differentially Responsive to MEK Inhibitor Due to AKT or STAT3 Activation: Implication for Combinatorial Approach
Young-Kwang Yoon et al.
MOLECULAR CARCINOGENESIS (2010)
Understanding resistance to EGFR inhibitors-impact on future treatment strategies
Deric L. Wheeler et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2010)
Trefoil Factor 3 Is Oncogenic and Mediates Anti-Estrogen Resistance in Human Mammary Carcinoma
Nagarajan Kannan et al.
NEOPLASIA (2010)
Aldehyde Dehydrogenase 1 Is a Tumor Stem Cell-Associated Marker in Lung Cancer
Feng Jiang et al.
MOLECULAR CANCER RESEARCH (2009)
Salivary trefoil factor 3 enhances migration of oral keratinocytes
Trond Storesund et al.
EUROPEAN JOURNAL OF ORAL SCIENCES (2008)
The international epidemiology of lung cancer - Geographical distribution and secular trends
Danny R. Youlden et al.
JOURNAL OF THORACIC ONCOLOGY (2008)
Trefoil factor 3 stimulates human and rodent pancreatic islet β-cell replication with retention of function
Patrick T. Fueger et al.
MOLECULAR ENDOCRINOLOGY (2008)
Raf kinases: Function, regulation and role in human cancer
Deborah T. Leicht et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH (2007)
K-ras mutations in non-small-cell lung carcinoma:: A review
Sarit Aviel-Ronen et al.
CLINICAL LUNG CANCER (2006)
The MEK/MAPK pathway is involved in the resistance of breast cancer cells to the EGFR tyrosine kinase inhibitor gefitinib
N Normanno et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2006)
BRAF mutation predicts sensitivity to MEK inhibition
DB Solit et al.
NATURE (2006)
Multiple regulatory pathways for trefoil factor (TFF) genes
M Baus-Loncar et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2005)
A-Raf and Raf-1 work together to influence transient ERK phosphorylation and Gl/S cell cycle progression
K Mercer et al.
ONCOGENE (2005)
Gene expression profile of gastric carcinoma: Identification of genes and tags potentially involved in invasion, metastasis, and carcinogenesis by serial analysis of gene expression
N Oue et al.
CANCER RESEARCH (2004)
Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer
J Rinehart et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Trefoil factor 3 is overexpressed in human prostate cancer
IP Garraway et al.
PROSTATE (2004)
Cl-1040 (PD184352), a targeted signal transduction inhibitor of MEK (MAPKK)
LF Allen et al.
SEMINARS IN ONCOLOGY (2003)
Distinct pathways of cell migration and antiapoptotic response to epithelial injury: Structure-function analysis of human intestinal trefoil factor
K Kinoshita et al.
MOLECULAR AND CELLULAR BIOLOGY (2000)
Share Paper
